Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats

Drug Development and Industrial Pharmacy

Volumn 37, Issue 12, 2011, Pages 1387-1393

  Ito, Yukako ^a   Kashiwara, Sumie ^a   Fukushima, Keizo ^a,b   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

array chip; bioavailability; Dissolving microneedles; rats; sumatriptan; transdermal delivery

Indexed keywords

DEXTRAN; HYALURONIC ACID; SUMATRIPTAN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISSOLVING MICRONEEDLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; MALE; MICROARRAY ANALYSIS; MICROTECHNOLOGY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT;

ADMINISTRATION, CUTANEOUS; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; MALE; NEEDLES; RATS; RATS, WISTAR; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SKIN ABSORPTION; SUMATRIPTAN;

EID: 80955135491     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.576426     Document Type: Article

References (31)

1. Leonardi M, Steiner TJ, Scher AT, Lipton RB. (2005). The global burden of migraine: Measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain, 6:429-440. (Pubitemid 43078769)
2. Robert E, Ryan JMD. (2001). Patient treatment preferences and the 5-HT1B/1D agonists. Arch Intern Med, 161:2545-2553.
3. Luthringer R, Djupesland PG, Sheldrake CD, Flint A, Boeijinga P, Danjou P et al. (2009). Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol, 61:1219-1228.
4. Dilone E, Bergstrom D, Cabana B, Nedumpara M, Fox AW; Sumatriptan Lingual Spray Study Group. (2009). Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. Headache, 49:1445-1453.
5. Volans GN. (1978). Migraine and drug absorption. Clin Pharmacokinet, 3:313-318. (Pubitemid 8375208)
6. Hussey EK, Aubert B, Richard I, Kunka RL, Fowler P. (1995). The clinical pharmacology of sumatriptan suppositories. Cephalgia, 15 S14: 223.
7. Rothrock JF. (2010). Injectable sumatriptan: Now needle-based or needle-free: Headache toolbox. Headache, 50:343-344.
8. Brandes JL, Cady RK, Freitag FG, Smith TR, Chandler P, Fox AW et al. (2009). Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache, 49:1435-1444.
9. Duquesnoy C, Mamet JP, Sumner D, Fuseaud E. (1998). Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci, 6:99-104. (Pubitemid 28164279)
10. Patel SR, Zhong H, Sharma A, Kalia YN. (2007). In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Eur J Pharm Biopharm, 66:296-301. (Pubitemid 46661905)
11. Siegel SJ, O'Neill C, Dube LM, Kaldeway P, Morris R, Jackson D et al. (2007). A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res, 24:1919-1926. (Pubitemid 47389248)
12. Henry S, McAllister DV, Allen MG, Prausnitz MR. (1998). Microfabricated micropiles: A novel approach to transdermal drug delivery. J Pharm. Sci, 187: 922-925. (Pubitemid 28381247)
13. Teo MA, Shearwood C, Ng KC, Lu J, Moochhala S. (2005). In vitro and in vivo characterization of MEMS microneedles. Biomed Microdevices, 7:47-52. (Pubitemid 40613130)
14. Park JH, Allen MG, Prausnitz MR. (2006). Polymer micropiles for control1ed-release drug delivery. Pharm Res, 23:1008-1019. (Pubitemid 43781409)
15. Davis SP, Martanto W, Allen MG, Prausnitz MR. (2005). Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans Biomed Eng, 52:909-915. (Pubitemid 40675490)
16. McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, Allen MG et al. (2003). Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci USA, 100:13755-13760. (Pubitemid 37499139)
17. Ito Y, Ohashi Y, Saeki A, Sugioka N, Takada K. (2008). Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. Chem Pharm Bull, 56:243-246. (Pubitemid 351463230)
18. Ito Y, Hagiwara E, Saeki A, Sugioka N, Takada K. (2006). Feasibility of microneedles for percutaneous absorption of insulin. Eur J Pharm Sci, 29:82-88. (Pubitemid 44279397)
19. Ito Y, Yoshimitsu J, Shiroyama K, Sugioka N, Takada K. (2006). Selfdissolving microneedles for the percutaneous absorption of EPO in mice. J Drug Target, 14:255-261. (Pubitemid 44173291)
20. Ito Y, Shiroyama K, Yoshimitsu J, Ohashi Y, Sugioka N, Takada K. (2007). Pharmacokinetic and pharmacodynamic studies following percutaneous absorption of erythropoietin micropiles to rats. J Control Release, 121:176-180. (Pubitemid 47212539)
21. Ito Y, Saeki A, Shiroyama K, Sugioka N, Takada K. (2008). Percutaneous absorption of interferon-alpha by self-dissolving micropiles. J Drug Target, 16:243-249. (Pubitemid 351460653)
22. Ito Y, Ohashi Y, Shiroyama K, Sugioka N, Takada K. (2008). Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats. Biol Pharm Bull, 31:1631-1633.
23. Naito Y, Shin'oka T, Hibino N, Matsumura G, Kurosawa H. (2008). A novel method to reduce pericardial adhesion: A combination technique with hyaluronic acid biocompatible membrane. J Thorac Cardiovasc Surg, 135:850-856. (Pubitemid 351417939)
24. Cheung RY, Ying Y, Rauth AM, Marcon N, Yu Wu X. (2005). Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin C. Biomaterials, 26:5375-5385. (Pubitemid 40462352)
25. Chen FM, Wu ZF, Sun HH, Wu H, Xin SN, Wang QT et al. (2006).Release of bioactive BMP from dextran-derived microspheres: a novel delivery concept. Int J Pharm, 307:23-32. (Pubitemid 41773248)
26. Takada K. (2008). Microfabrication-derived DDS: From batch to individual production. Drug Discov Ther, 2: 140-155.
27. Tan A, Hang P, Couture J, Hussain S, Vallee F. (2007). An evaporation-free solid-phase extraction method for rapid and accurate analysis of sumatriptan in human plasma by LC-MS/ MS. J Chromatogr B Analyt Technol Biomed Life Sci, 856: 9-14. (Pubitemid 47302898)
28. Ferrari A, Pinetti D, Bertolini A, Coccia C, Sternieri E. (2008). Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol, 64:489-495.
29. Maas HJ, Spruit MA, Danhof M, Della Pasqua OE. (2008). Relevance of absorption rate and lag time to the onset of action in migraine. Clin Pharmacokinet, 47:139-146.
30. Rapoport A, Winner P. (2006). Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache, 46 Suppl 4:S192-S201. (Pubitemid 44656904)
31. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T. (2009). Zelrix: a novel transdermal formulation of sumatriptan. Headache, 49:817-825.